Previous issue | Volume 84 | ESPE2015 | Next issue

54th Annual ESPE

Barcelona, Spain
01 Oct 2015 - 03 Oct 2015

Card image cap
Barcelona, Spain; 1-3 October 2015 Further information

Poster Category 3

GH & IGF

Serum IGFI Concentration and Growth During Infancy Correlate to Polyunsaturated Fatty Acid Pattern
aGP-GRC, Inst for Clinical Sciences, Gothenburg University, Gothenburg, Sweden; bDepartment of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden
hrp0084p3-917
Are Short Children with Low GH Secretion Metabolically Different from Children of Normal Height?
aDepartment of Women’s and Children’s Health, Karolinska Institute, Stockholm, Sweden; bDepartment of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm, Sweden
hrp0084p3-918
Familial Short Stature Associated to Terminal Microdeletion of 15q26.3: Variable Phenotype not Involving the IGF1 Receptor Gene
aPediatric Unit, Department of Medical and Surgical Sciences of the Mother, Children and Adults, University of Modena and Reggio Emilia, Modena, Italy; bMedical Genetics, Department of Medical and Surgical Sciences, University Hospital of Modena, Modena, Italy
hrp0084p3-919
Is the Insulin Secretion in Pancreatic Beta Cells Related with IGF-1/IGFBP-1 Axis in Korean Children?
Pediatrics, Chonbuk National University Medical School, Jeonju-si, Republic of Korea
hrp0084p3-920
Severe Isolated Growth Hormone Deficiency and Myopathy in Two Brothers with RNPC3 Mutation
aMedical Faculty Skopje, Skopje, Macedonia; bMacedonian Academy of Sciences and Arts, Skopje, Macedonia; cHopital Trousseau, Paris, France; dUniversity of Leipzig Medical School, Leipzig, Germany; ePerth Campus, Perth, Australia
hrp0084p3-921
Gigantism Secondary to Growth Hormone Secreting Pituitary Macrodenoma
National University Hospital, Singapore, Singapore
hrp0084p3-922
IGFI and Relation to Growth in Infancy and Early Childhood in Very-Low-Birth-Weight Infants and Term Appropriate for Gestational Age Infants
aVU University Medical Center, Amsterdam, The Netherlands; bAlbert Schweitzer Hospital, Dordrecht, The Netherlands
hrp0084p3-923
Severe Isolated Growth Hormone Deficiency and Myopathy in Two Brothers With RNPC3 Mutation
aMedical Faculty Skopje, Skopje, Macedonia; bMacedonian Academy of Sciences and Arts, Skopje, Macedonia; cHopital Trousseau, Paris, France; dUniversity of Leipzig Medical School, Leipzig, Germany; ePerth Campus, Perth, WA, Australia
hrp0084p3-924
Comparison of Two IGF1 Assays in Patients Treated with GH
aGermans Trias i Pujol Hospital, Badalona, Spain; bFoundation Leo Messi, Badalona, Spain
hrp0084p3-927
Acute Effects of a Training Session on IGF1 and IGFBP3 Concentrations in Brazilian Jiu-Jitsu Fighters
aRibeirão Preto School of Physical Education and Sport-USP, Ribeirão Preto, Brazil; bDepartment of Paediatrics, Ribeirão Preto Medical School-USP, Ribeirão Preto, Brazil
hrp0084p3-928
Biochemical Profiles Differentials by SGA Children Catch Up
aUniversity Hospital of Alava, Vitoria, Spain; bGrupo Nutrición y Obesidad, Facultad de Farmacia, Vitoria, Spain; cCiberobn, Instituto de Salud Carlos III, Madrid, Spain
hrp0084p3-929
5-Year Response to GH in Children with Noonan Syndrome and GH Deficiency: Our Experience and Review of the Literature
aFondazione IRCCS Pliclinico San Matteo, University of Pavia, Pavia, Italy; bFondazione IRCCS Policlinico San Matteo, Pavia, Italy; cSpedali Civili, University of Brescia, Brescia, Italy
hrp0084p3-931
Modification of Cardiovascular Risk Factors in Children Treated with GH
aHospital Verge de la Cinta, Tortosa, Spain; bHospital Joan XXIII, Tarragona, Spain; cCAP Sant Pere, Reus, Spain; dCAP Roquetes, Tortosa, Spain; eCentro de salud de Burjasot, Valencia, Spain; fCAP Rambla Nova, Tarragona, Spain
hrp0084p3-932
Adult Height in Children Born Small for Gestational Age and Treated with GH: Data from the French KIGS Database
aHôpital Universitaire Necker Enfants Malades, APHP, Paris, France; bUniversité Paris Descartes, Paris, France
hrp0084p3-933
Psychosocial Functioning and Self-Perception of Children and Adolescents Treated with GH
aDepartment of Endocrinology Growth and Developement, Children’s Hospital P. & A. Kyriakou, Athens, Greece; bNational and Kapodistrian University, Athens, Greece
hrp0084p3-934
Adherence to GH Treatment: Impact of Actual Height, Treatment Duration, and Puberty
aVestische Children Hospital, Datteln, Germany; bGKM Gesellschaft fuer Therapieforschung mbH, Munich, Germany; cMerck Serono GmbH, Damrstadt, Germany; dDepartment of Pediatric Endocrinology and Diabetology, University Children’s Hospital, University Duisburg-Essen, Essen, Germany
hrp0084p3-936
The Blood Oxidant System and Insulin Resistance in Girls with Turner Syndrome after 1 Year of GH Therapy
aDepartment of Pediatric Endocrinology, Endocrinology Research Center, Moscow, Russia; bBiophysics Department, Faculty of Biology, Moscow State University, Moscow, Russia
hrp0084p3-937
An Open-Label Phase 2 Dose-Finding Study Comparing Three Different Doses of Weekly TV-1106 and Daily Recombinant Human GH (Genotropin[reg]) in Treatment-Naive, Pre-Pubertal, GH-Deficient Children
aSTAT5 Consulting, LLC; Oregon Health & Science University, Portland OR, USA; bDepartment of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands; cBashkir State Medical University, Ufa, Russia; dInstitute of Endocrinology and Metabolism, Kiev, Ukraine; eClinical Development Teva Pharmaceuticals, Frazer PA, USA; fBiostatistics Teva Pharmaceuticals Ltd, Netanya, Israel; gBiostatistics Teva Pharmaceuticals Ltd, West Chester PA, USA; hResearch and Development Teva Pharmaceuticals Ltd, Netanya, Israel
hrp0084p3-938
Increasing Lean Body Mass, Phase Angle, and Total Body Water But Decreasing Body Fat Among Short-statured Children Born Small-for-Gestational Age on GH Treatment
Division of Paediatric Endocrinology and Diabetology, Department of Paediatrics and Adolescent Medicine, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany
hrp0084p3-939
GH Dosing Patterns in Children with Isolated GH Deficiency and Multiple Pituitary Hormone Deficiency Enrolled in the NordiNet[reg] International Outcome Study
aCharles University and University Hospital Motol, Prague, Czech Republic; bNovo Nordisk A/S, Søborg, Denmark; cNovo Nordisk Health Care AG, Zurich, Switzerland; dCharité – Universitätsmedizin Berlin, Berlin, Germany
hrp0084p3-940
Decrease of Small Dense LDL and Lipoprotein-Associated Phospholipase A2 due to Human GH Treatment in Short Children with GH Deficiency and Small for Gestational Age Status
aDepartment of Pediatrics and Adolescent Medicine, University Medical Center, Freiburg, Germany; bDepartment of Clinical Chemistry, University Medical Center, Freiburg, Germany.
hrp0084p3-941
Influence of the Application of the POI Score on the Results of GH Therapy in Prader-Willi
aUniversity of Insubria, Varese, Italy; bBambino Gesù Children’s Hospital, Palidoro-Rome, Italy; cSan Raffaele Hospital, Università Vita e Salute, Milan, Italy; dDivision of Auxology, Istituto Auxologico Italiano, Verbania, Italy; ePediatric Unit, University of Modena e Reggio, Modena, Italy; fENT Unit, Ospedale di Circolo, Insubria University, Varese, Italy; gPediatric Unit, Spedali Civili, Brescia, Italy
hrp0084p3-943
The Impact of GH Therapy in Noonan Syndrome Children with Identified Mutations in RAS/MAPK Pathway
aDepartamento de Pediatria, Faculdade de Ciencias Medicas da Santa Casa de Sao Paulo, Sao Paulo, Brazil; bUnidade de Endocrinologia-Genetica, LIM/25, Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil; cUnidade de Genetica, Instituto da Crianca, FMUSP, Sao Paulo, Brazil; dLaboratorio de Hormonios e Genetica Molecular (LIM/42), Unidade de Endocrinologia do Desenvolvimento, Hospital das Clinicas, FMUSP, Sao Paulo, Brazil; eLaboratorio de Genetica e Cardiologia Molecular, Instituto do Coraçao (InCor), Sao Paulo, Brazil
hrp0084p3-944
As Great Intra as Interindividual Variability in Uptake of s.c. GH Injections in Longitudinally Followed GH Treated Children
aDepartment of Pediatrics, Institute of Clinical Sciences, Umeå University, Umeå, Sweden; bDepartment of Pediatrics, Göteborg Pediatric Growth Research Center, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sweden, Göteborg, Sweden; cDepartment of Physiology/Endocrinology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Göteborg, Sweden, Göteborg, Sweden
hrp0084p3-945
Medical and Biochemical Effects of Intervention Program in Patients with Poor Adherence to rhGH Treatment
aGermans Trias i Pujol Hospital, Badalona, Spain; bFellow Foundation Leo Messi, Badalona, Spain
hrp0084p3-947
Plexiform Neurofibroma and Demielinisant Lesions in a Patient with GH Deficiency Treated with rGH
aPOSDRU/159/1.5/S/141531, Victor Babes Institute, Bucharest, Romania; b‘Carol Davila’ University of Medicine and Pharmacy, Bucharest, Romania; cDepartment of Endocrinology, Elias Hospital, Bucharest, Romania
hrp0084p3-949
Growth, Development and Puberty of Patients with Congenital Multiple Pituitary Hormone Deficiencies
aSchneider Children’s Medical Center, Petah Tikva, Israel; bSackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
hrp0084p3-950
Predictors of Response to rhGH Treatment in 125 Children with Short Stature of Various Aetiologies
aRegina Margherita Children Hospital, Città della Salute, Torino, Italy; bDepartment of Public Health and Paediatrics, University of Torino, Torino, Italy
hrp0084p3-951
Linear Regression Model of Final Height Prediction Based on Pre-Treatment Data in Children with GH Deficiency Treated with GH
aDepartment of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital – Research Institute, Lodz, Poland; bDepartment of Automatics and Biomedical Engineering, AGH University of Science and Technology, Cracow, Poland
hrp0084p3-952
Long-Term Effects of GH Replacement Therapy on Hematopoiesis in GH Deficient Children
Pediatric Endocrinology Unit, Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
hrp0084p3-954
A 5-year Follow-up of Adults, with Childhood-Onset GH Deficiency, Treated with GENOTONORM[reg] in France
aService D’endocrinologie Et Medecine De la Reproduction, Hôpital Universitaire Pitié-Salpêtrière, APHP, Paris, France; bFédération d’Endocrinologie Lyon Est, Groupement Hospitalier Est, Bron, France; cService D’endocrinologie, Diabète et Nutrition, Hôpital Robert Debré, CHU de Reims, Reims, France; dService D’endocrinologie, Hôpital De la Timone, AP-HM, Marseille, France
hrp0084p3-956
Somatotropic Pituitary Insufficiency in Kearns-Sayre Syndrome - The Clinical Picture, Genetic Diagnosis and Efficacy of rhGH Therapy
aSecond Chair of Pediatrics, Department of Pediatric Endocrinology and Rheumatology, Molecular Endocrinology Laboratory, Poznan University of Medical Sciences, Poznan, Poland; bSecond Chair of Pediatrics, Department of Pediatric Endocrinology and Rheumatology, Karol Jonsher Hospital, Poznan, Poland
hrp0084p3-957
Late Diagnosis of a Type II/III Mucolipidoses Treated with GH Replacement Therapy
aUniversity of Medicine and Pharmacy Gr T Popa, Iasi, Romania; bEndocrinology Department, Sfantul Spiridon University Hospital, Iasi, Romania; cDepartment of Human Genetics, Sfanta Maria Hospital, Iasi, Romania
hrp0084p3-959
Does Applying Regular Questionnaire to Patients on GH Increase the Compliance?
Division of Pediatric Endocrinology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
hrp0084p3-960
Characterisation of Children Born Small for Gestational Age within the Australian Indications for GH (GH) Therapy: An OZGROW Analysis
aMater Reseatch UQ Institute, South Brisbane, QLD, Australia; bLady Cilento Children’s Hospital, South Brisbane, QLD, Australia; cAPEG-OZGROW, Morisset, NSW, Australia
hrp0084p3-961
The Easypod[trade] Connect Observational Study: Comparison of Results from Interim Analyses
aChildren’s Nutrition Research Centre, Queensland Children’s Medical Research Institute, University of Queensland, Brisbane, QND, Australia; bDivision of Pediatric Endocrinology, Hôpital Femme-Mère-Enfant, Lyon, France; cDepartment of Pediatric Medicine, Karolinska University Hospital, Stockholm, Sweden; dEMD Serono, Mississauga, Canada; eMerck KGaA, Darmstadt, Germany; fFaculty of Health Sciences, McMaster Children’s Hospital and McMaster University, Hamilton, Canada
hrp0084p3-963
Evaluation of the Facility of Use of a New GH Administration Device - Study DAGH2014
aPediatrics Department, University Hospital of Fuenlabrada, Madrid, Spain; bPharmacy Department, University Hospital of Fuenlabrada, Madrid, Spain
hrp0084p3-964
Effect of Human Growth Hormone on Growth Rate of Short Stature Children with Low Birth Weight
aMetabolic Diseases Research Center, Qazvin University of Medical Sciences, Qazvin, Qazvin, Iran; bChildren Growth and Development Research Center, Qazvin University of Medical Sciences, Qazvin, Qazvin, Iran; cQazvin University of Medical Sciences, Qazvin, Qazvin, Iran
hrp0084p3-965
GH Treatment and First Year Response: A Retrospective Study
Endocrinology, Diabetes and Metabolism Department, Hospital de Egas Moniz, CHLO-EPE, Lisbon, Portugal
hrp0084p3-966
Usefulness of Reevaluation of Growth Hormone Secretion During Puberty
Department of Life and Reproduction Sciences, Pediatric Clinic, University of Verona, Verona, Italy
hrp0084p3-967
Patients with Childhood Onset Growth Hormone Deficiency Treated with rhGH - Reevaluation in the Transition Period between Childhood and Adulthood - Preliminary Study
a“C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania; b“Coltea” Clinical Hospital, Bucharest, Romania; c“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
hrp0084p3-971
Time Trends in Baseline Characteristics (2006-2014) in Short Children with Growth Hormone Deficiency (GHD), Born Small for Gestational Age (SGA) and with Ullrich-Turner Syndrome (TS) Enrolled in Nordinet[reg] International Outcomes Study (IOS) in Germany and Czech Republic
aHospital for Children and Adolescents, University of Erlangen, Erlangen, Germany; bUniversity Children’s Hospital, Münster, Germany; cNovo Nordisk Germany, Mainz, Germany; dNovo Nordisk Health Care AG, Zurich, Switzerland; eNovo Nordisk A/S, Søborg, Denmark; fCharles University and University Hospital Motol, Prague, Czech Republic
hrp0084p3-972
A Patient with an 13q Deletion Syndrome, Important Growth Delay and Somatotropine Insufficiency Undergoing Growth Hormone Therapy-Case Report.
aClinic of Endocrinology and Diabetology, The Children’s Health Memorial Institute, Warsaw, Poland; bHealth Science Department, Jan Kazimierz University, Kielce, Poland; cGenetics Department, The Children’s Health Memorial Institute, Warsaw, Poland
hrp0084p3-973
Linear Growth in a Child with Ellis Van Creveld Syndrome: Positive Effect of Growth Hormone Therapy
aUniversity of Alexandria College of Medicine, Alexandria, Egypt; bHamad General Hospital, Doha, Qatar
hrp0084p3-974
Factors Effecting Response to Growth Hormone Treatment in Children with Turner Syndrome
Department of Pediatric Endocrinology and Diabetes, Marmara University, Istanbul, Turkey
hrp0084p3-975
Thyroid Function in Children with Prader-Willi Syndrome, the First 12 Months of GH Therapy
aLady Cilento Children’s Hospital, Brisbane, QND, Australia; bMater Research Institute, University of Queensland, Brisbane, QND, Australia
hrp0084p3-976
Current Practice in Diagnosis and Treatment of GH Deficiency in Childhood: A Survey from Turkey
aPediatric Endocrinology Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey; bPediatric Endocrinology Unit, Bakirkoy Dr Sadi Konuk Hospital, Istanbul, Turkey; cPediatric Endocrinology Unit, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey; dPediatric Endocrinology Unit, Faculty of Medicine, Gazi University, Ankara, Turkey; ePediatric Endocrinology Unit, Faculty of Medicine, Akdeniz University, Antalya, Turkey; fPediatric Endocrinology Unit, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey; gPediatric Endocrinology Unit, Tepecik Research and Training Hospital, Izmir, Turkey; hPediatric Endocrinology Unit, Faculty of Medicine, Ege University, Izmir, Turkey; iPediatric Endocrinology Unit, Faculty of Medicine, Celal Bayar University, Manisa, Turkey; jPediatric Endocrinology Unit, Goztepe Educational and Research Hospital, Istanbul, Turkey; kPediatric Endocrinology Unit, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey; lPediatric Endocrinology Unit, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey; mPediatric Endocrinology Unit, Faculty of Medicine, Erciyes University, Kayseri, Turkey; nDiyarbakir Children’s State Hospital and Diyarbakir Training and Research Hospital, Diyarbakir, Turkey; oPediatric Endocrinology Unit, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey; pPediatric Endocrinology Unit, Faculty of Medicine, Ankara University, Ankara, Turkey; qPediatric Endocrinology Unit, Faculty of Medicine, Osman Gazi University, Eskisehir, Turkey; rPediatric Endocrinology Unit, Faculty of Medicine, Marmara University, Istanbul, Turkey; sPediatric Endocrinology Unit, Faculty of Medicine, Cukurova Universitesi, Adana, Turkey
hrp0084p3-981
Experience of the Use of Genetically Engineered GH 'Rastan' by Children in Clinical Practice
aOrenburg Children’s Clinical Hospital, Orenburg, Russia; bPerm Regional Children’s Clinical Hospital, Perm, Russia
hrp0084p3-982
GH Therapy in Kuwait: First Report on Characteristics and Response in Treated Children
aFaculty of Medicine, Kuwait Univesity, Kuwait, Kuwait; bMinistry of Health, Kuwait, Kuwait
hrp0084p3-983